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Abstract
Biomarkers for neurodegeneration could be early prognostic measures of brain damage and dysfunction in aneurysmal
subarachnoid hemorrhage (aSAH) with clinical and medical applications. Recently, we developed a new panel of
neurodegeneration biomarkers, and report here on their relationships with pathophysiological complications and outcomes
following severe aSAH. Fourteen patients provided serial cerebrospinal fluid samples for up to 10 days and were evaluated
by ultrasonography, angiography, magnetic resonance imaging, and clinical examination. Functional outcomes were
assessed at hospital discharge and 6–9 months thereafter. Eight biomarkers for acute brain damage were quantified:
calpain-derived a-spectrin N- and C-terminal fragments (CCSntf and CCSctf), hypophosphorylated neurofilament H, 14-3-3
b and f, ubiquitin C-terminal hydrolase L1, neuron-specific enolase, and S100b. All 8 biomarkers rose up to 100-fold in a
subset of patients. Better than any single biomarker, a set of 6 correlated significantly with cerebral vasospasm, brain
infarction, and poor outcome. Furthermore, CSF levels of 14-3-3b, CCSntf, and NSE were early predictors of subsequent
moderate-to-severe vasospasm. These data provide evidence that a panel of neurodegeneration biomarkers may predict
lasting brain dysfunction and the pathophysiological processes that lead to it following aSAH. The panel may be valuable as
surrogate endpoints for controlled clinical evaluation of treatment interventions and for guiding aSAH patient care.
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Introduction
Subarachnoid hemorrhage (SAH), a severe form of hemorrhag-
ic stroke caused by rupture of a brain aneurysm, affects 30,000
people annually in the United States [1,2]. Of the 85% of patients
who survive the initial aneurysmal SAH, approximately one-third
develop further brain injury [2]. The majority of morbidity and
mortality after aSAH is due to delayed cerebral ischemia (DCI)
[3]. The cause of DCI has traditionally been ascribed to cerebral
vasospasm, a narrowing of the cerebral arteries. However,
therapies aimed at ameliorating vasospasm are only partially
effective at preventing DCI [4]. DCI is defined clinically as focal
neurological impairment or deterioration in neurological function
on the Glasgow Coma Scale [5], and is correlated with
radiographic evidence of cerebral infarction [6]. DCI typically
occurs between 4–14 days after aSAH. Currently, there are few
effective therapies for the prevention and treatment of DCI.
Biochemical markers for neurodegeneration of aSAH could
increase the speed and discriminative power and reduce the cost of
clinical research by serving as surrogate endpoints for experimen-
tal or non-optimized therapies. Such markers might also guide
patient care through early detection of complications leading to
DCI and long-term brain dysfunction. A number of proteins
normally expressed predominantly in the nervous system increase
markedly in cerebrospinal fluid (CSF) during the acute period
following aneurysm rupture, and have been associated with
increased patient mortality, morbidity and long-term brain
dysfunction [7–12]. However, owing to one or more limitations
in sensitivity, specificity, and reliability, no individual surrogate
marker is widely accepted to predict vasospasm, DCI, or patient
outcomes, or otherwise guide patient care [13]. To overcome these
obstacles, we recently identified several new candidate protein
markers for neurodegeneration and developed a novel biomarker
panel for acute brain damage. Among the most abundant proteins
released by degenerating neurons, several expressed predominant-
ly or exclusively in the nervous system rise markedly in the CSF
and blood of experimental animals subjected to ischemia- or
trauma-induced acute brain damage [14], in some cases
proportional to the severity of acute brain histopathology [15].
Moreover, several of the markers rise in the CSF and blood of
human patients following surgically-induced circulatory arrest or
traumatic brain injury, suggesting they might serve broadly in
humans as biochemical indices of brain damage [16–19]. At least
two, calpain-derived N- and C-terminal proteolytic fragments of
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28938the a-subunit of the actin-binding protein spectrin, are mecha-
nism-based markers for the calpain-driven necrotic mode of
neurodegeneration [20,21] that is a major contributor to ischemic
brain damage [22–24]. Here, we examined the prognostic utility
of this panel of neurodegeneration biomarkers in severe aSAH in
conjunction with widely studied neuronal and astroglial markers of
acute brain damage, neuron-specific enolase and S100b, respec-
tively. The kinetics and magnitude of CSF neurodegeneration
biomarker alterations for up to 10 days after aneurysm rupture
were compared with angiographic and ultrasonographic evidence
for cerebral vasospasm, with clinical and neuroradiological
evidence of brain ischemia and infarction, and with the degree
of brain dysfunction at hospital discharge and long-term follow-up.
Materials and Methods
Ethics Statement
The study protocol was approved by the University of
Pennsylvania Institutional Review Board (protocol #803321). All
patients or their surrogates provided written informed consent. In
cases where the patient was unconscious or cognitively impaired,
written informed consent was obtained from the subject’s
authorized representative. All patient information was kept
confidential in accordance with the Health Insurance Portability
and Accountability Act.
Aneurysmal subarachnoid hemorrhage patients
Twenty-five patients were recruited between 2007 and 2010.
Inclusion criteria included: age between 18 and 80, Fisher group 3
or 4, and the presence of a saccular aneurysm confirmed by
cerebral angiography. Patients presenting to the hospital more
than 48 hours after ictus were excluded. Demographic data, Fisher
group and Hunt and Hess grades were recorded on admission.
Blood sampling was performed on the day of aneurysmal rupture
and on post-hemorrhage days (PHD) 1,3,5,7 and 10. Magnetic
resonance imaging was performed on PHD 14 in all surviving
patients without a contraindication. Patients were treated
according to a standard local protocol for the management of
SAH [25]. Aneurysms were secured with either endovascular
coiling or surgical clipping within 24 hours of presentation.
Nimodipine was administered for 21 days. Anti-epileptic medica-
tions were administered for 7 days after ictus in the absence of
seizures. Ventriculostomy catheters were placed in patients with a
GCS ,8 or with clinically significant hydrocephalus (n=14).
Monitoring for cerebral vasospasm was routinely performed
with daily trans-cranial Doppler (TCD) ultrasound, and post-
operative angiography, while neurological evaluations evaluated
the presence of DCI. TCD vasospasm was defined as a mean
blood flow velocity greater than 125 cm/s in the anterior
circulation or greater than 100 cm/s in the posterior circulation
in addition to a Lindegaard ratio (mean middle cerebral artery
flow velocity/mean cervical internal carotid artery flow velocity) of
greater than 3. Normal saline solution and vasopressors were
administered to improve neurological deficits in patients with
suspected DCI. If symptoms persisted or were refractory to these
measures, intra-arterial treatments were employed (e.g., intra-
arterial nicardipine or balloon angioplasty). The degree of
angiographic vasospasm was stratified by the percent luminal
reduction in the most severely afflicted vessel [26]: 1–24% mild;
25–50% moderate; severe .50%. Any evidence of ischemia on
diffusion-weighted imaging was recorded as radiographic infarc-
tion. The Glasgow Outcome Scale – Extended (GOSE) and
modified Rankin Scale (mRS) were obtained at 6–9 months after
discharge by telephone interview or mailed questionnaire. These
procedures were performed by investigators blinded to the
neurodegeneration biomarker findings.
Quantification of neurodegeneration biomarkers
Eight markers were measured serially in CSF, five by a
quantitative near-infrared Western blot technique and the
remaining three by enzyme-linked immunofluorescence assays.
These measurements were made by an investigator blinded to the
clinical data. For the immunoblotting, the following antibodies
were used: mouse anti-a-spectrin (MAB1622 at 1/1000; Milli-
pore); mouse anti-14-3-3b (Santa Cruz #25276 at 1/1000); rabbit
anti-14-3-3f (Santa Cruz SC-1019 at 1/1000); mouse anti-UCH-
L1 (Abcam AB72911 at 1/1000); mouse anti-NSE (Abcam
AB10169 at 1/1000). The secondary anti-rabbit and anti-mouse
antibodies fluorescing in the near-infrared range were purchased
from Licor, and used at 1/15,000 dilution. Images were captured
using an Odyssey near-infrared system under conditions where
serial dilutions of the protein load produced linear changes in band
density.
Sandwich enzyme-linked immunofluorescence assays
The enzyme-linked fluorescence immunoassays for calpain-
cleaved a-spectrin N-terminal fragment and hypophosphorylated
neurofilament H (NFHsmi35) use a mouse monoclonal capture
antibody, a rabbit detecting antibody, and mouse-anti-rabbit IgG
conjugated to horseradish peroxidase as the reporter probe. These
immunoassays have been characterized and described in detail
before [17]. Each assay was normalized using serial 2-fold
dilutions of standard proteins: brain extract treated with activated
calpain and a purified bovine spinal cord neurofilament
preparation, respectively.
For the S100b sandwich ELISA, the S100b capture antibody
(Abcam AB8334 at 1/10,000 dilution) was adsorbed onto Nunc
maxisorp 96 well plates overnight at 4uC in 50 mM sodium
carbonate buffer. After any remaining protein binding sites were
blocked with 1% normal mouse serum in Tris-buffered saline
supplemented with 0.05% Tween-20 (TTBS, pH 7.4), wells were
washed four times in TTBS, then human CSF at 1% or varying
concentrations of recombinant human S100b standards (Genway
#288258) prepared in normal mouse serum in TTBS supple-
mented with 1 mM CaCl2 were added for 90 minutes at 22uC
(100 ml per well). Wells were washed four times in TTBS, then the
biotinylated anti-S100b detecting antibody was added (Abcam
AB20327 at 1/5000 dilution in normal mouse serum/TTBS/
1 mM CaCl2) for 1 hour at 22uC. This antibody was prepared by
dialysis against phosphate-buffered saline (pH 7.4), followed by
reaction with a 50-fold molar excess of N-hydroxysuccinimido-
biotin as recommended by the manufacturer (Pierce EZ-Link
biotin). After another four washes in TTBS, the streptavidin-
horseradish peroxidase reporter probe was added (Invitrogen; 1/
20,000 in 0.2% bovine serum albumin in TTBS/1 mM CaCl2)
and incubated for 1 hour at 22uC. After four more washes in
TTBS, the fluorogenic horseradish peroxidase substrate warmed
to 37uC was added to each well. The substrate consisted of
Amplex Ultrared (Invitrogen) prepared in 50 mM sodium citrate
(pH 6.4) plus 0.003% hydrogen peroxide. Fluorescent product
generated over 30 minutes at 37uC was measured using a plate-
reading spectrofluorimeter (Packard Fluorocount) set for 485 nm
excitation and 590 nm emission. Linear regression analysis of the
S100b standards provided for normalization of CSF S100b levels
across experiments.
For graphical representation of CSF levels of the eight
biomarkers measured serially for up to 10 days for 14 aSAH
cases, the marker concentrations were grouped into four
Biomarker Panel for SAH
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markers, 60% of the data points were classified as undetectable/
low, 20% as medium, 10% as high, and 10% as very high. The
peak units of each marker were coded as follows: CCSctf - 0–0.6
(blue), 0.61–2.0 (yellow), 2.01–5.0 (orange), 5.01-higher (red);
NFHsmi35–0.3.0 (blue), 3.1–6.0 (yellow), 6.1–30 (orange), 30.1–
higher (red); 14-3-3b - 0-3.0 (blue), 3.1–10 (yellow), 10.1–21
(orange), 21.1-higher (red); CCSntf – 0–4 (blue), 4.1–11 (yellow),
11.1–30 (orange), 30.1-higher (red); 14-3-3f - 0-3.9 (blue), 4.0–
10.0 (yellow), 10.1–30 (orange), 30.1-higher (red); UCH-L1 – 0–
3.0 (blue), 3.1–6.0 (yellow), 6.1–15.0 (orange), 15.1-higher (red);
NSE – 0–3.0 (blue), 3.1–6 (yellow), 6.1–15.0 (orange), 15.1-higher
(red); S100b - 0–40 (blue), 41–100 (yellow), 101–200 (orange),
201–higher (red).
For statistical analysis, the peak CSF level of each neurodegen-
eration biomarker was compared between groups dichotomized
with respect to initial hemorrhage severity, radiological infarction,
angiographic vasospasm, outcome at hospital discharge, and long-
term outcome using two-tailed t-test.
Results
Severe aneurysmal subarachnoid hemorrhage patients
enrolling in the neurodegeneration biomarker study
The demographics of the 25 severe aSAH patients enrolling in
the current study are summarized in Table 1. Two of the patients
withdrew from the study during the first 5 days of care and a third
expired. Of the remaining 22 patients, 15 received a ventriculos-
tomy and so provided serial CSF samples for neurodegeneration
biomarker analyses. These patients arethe focus of the remainder of
the manuscript. For one patient (case 16), the ventricular drain did
not remain patent and could not be replaced. Among the remaining
14 cases, 5 developed moderate to severe vasospasm beginning 5
days after aneurysm rupture as indicated by catheter angiography,
and confirmed by increased TCD flow velocities and worsening of
neurological symptoms. Twelve of the patients were evaluated for
brain infarction two weeks after aneurysm rupture by diffusion-
weighted MRI, and 6 had one or more foci of cerebral infarction.
Eleven provided serial CSF samples and survived to hospital
discharge. Based on their functional disabilities 2 returned home, 7
were discharged to an acute in-patient rehabilitation facility, and 2
were discharged to a skilled nursing facility. Among the 14 cases
providing serial CSF samples, long-term outcome assessments by
the GOSE and mRS were completed for 11 patients.
The CSF levels of neurodegeneration biomarkers vary
markedly over time and across aSAH patients
In addition to the neuron-enriched protein NSE and the
astroglial-enriched protein S100b, which have been studied
extensively as markers for acute brain damage, we measured serial
CSF alterations in the neurodegeneration biomarkers 14-3-3f,1 4 -
3-3b, calpain-cleaved a-spectrin N-terminal (CCSntf) and C-
terminal fragments (CCSctf), ubiquitin C-terminal hydrolase L1
(UCH-L1), and a hypophosphorylated form of the high molecular
weight neurofilament polypeptide (NFHsmi-35). These latter 6
proteins and NSE are expressed predominantly in neurons, are
released upon neuronal degeneration [12–14] and, in the case ofthe
two calpain derived proteolytic fragments, are generated preferen-
tially in neurons undergoing calpain-driven necrosis [20,22,27]. All
7 of the neuronal protein markers along with S100b rose in a subset
of aSAH patients during the post-hemorrhage period, and their
levels varied markedly over time and acrosspatients. Examples for 3
patients of the time- and patient-dependent CSF increases in the
neurodegeneration biomarkers 14-3-3b, CCSctf, and UCH-L1 are
shown in Figure 1. Case 25 exhibited large, rapid CSF elevations in
these three proteins (Figure 1A), as well as all other members of the
neurodegeneration biomarker panel. For case 9, on the other hand,
neurodegeneration biomarkers were near the lower limit of
detection to 3 days post-rupture, and rose either modestly (CCSctf)
or markedly(14-3-3b, UCH-L1) beginning on day 5. Case 19 is an
example in which CSFlevels of every neurodegeneration biomarker
were relatively low over the entire 7–10 day post-rupture period.
The peak CSF levels of the neurodegeneration biomarkers
differed dramatically across aSAH patients. The CSF levels of one
marker at a single time point post-rupture across 13 patients are
illustrated in Figure 1B. At 5 days, CCSctf levels differed more
than 100-fold between patients. The antibody recognizing CCSctf
(,150 kDa) also reacts with intact a-spectrin (,250 kDa) and a
smaller caspase-derived spectrin fragment (,120 kDa) [28] but,
unlike the calpain derivative, the levels of intact a-spectrin were
low and variable across patients, and the caspase derivative was
near the lower limit of detection in every case.
The varying magnitudes and time courses for CSF elevations in
the entire panel of 7 neurodegeneration biomarkers and S100b are
summarized in Figure 2. To depict in a simplified fashion data for
8 markers measured in 14 patients at up to 5 time points, marker
levels were categorized by color as either undetectable/low (blue),
medium (yellow), high (orange), or very high (red). From this
Table 1. Aneurysmal subarachnoid hemorrhage patient
demographics.
Case # Gender HH/F Grade Race Age Serial CSF
1F 1 / 3 A A 4 5 N o
2 F 4/3 C 37 No
3 F 5/3 C 54 Yes
4 F 2/3 C 49 No
5F K H3 5 N o
6M 1 / 3 A A 6 0 N o
7F 1 / 3 A A 5 3 N o
8 M 1/3 C 51 No
9 F 2/3 C 51 Yes
10 F 2/3 C 51 Yes
11 F 2/3 C 26 No
12 F 5/4 C 57 Yes
13 M 5/4 H 63 Yes
14 M Withdrawn C 48 No
15 F 3/3 H 56 Yes
16 F 2/3 C 47 No
17 F 2/4 C 38 Yes
18 M 5/4 C 59 Yes
19 F 3/3 C 51 Yes
20 F Withdrawn C 67 No
21 F 4/4 AA 67 Yes
22 F 3/4 C 52 Yes
23 M 2/3 AA 50 Yes
24 M 4/3 C 51 Yes
25 F 5/4 AA 49 Yes
Abbreviations: HH/F – Hunt-Hess/Fisher scale; C – Caucasian; H – Hispanic; AA –
African-American.
doi:10.1371/journal.pone.0028938.t001
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the neurodegeneration biomarker findings. Some patients dem-
onstrated low or undetectable marker elevations over the entire 7–
10 day post-hemorrhage period for most or all of the markers
(cases 15, 17, 19, 22, 23). For other cases, most of the biomarkers
increased only moderately (cases 12, 18, 24). Finally, in a third set
of cases levels of the 7 neuron-enriched biomarkers (the entire
panel less S100b) rose markedly (cases 3, 10, 13, 21, 25).
The 7 neurodegeneration biomarkers and S100b declined at
different rates after reaching peak levels, providing evidence for
their differential turnover in the CSF compartment. For example,
CCSctf has a short half-life in human CSF as evidenced by its
,80-fold decline in case 25 from day 1 to 3. Although steady-state
levels of these markers are dependent not only on their rates of
clearance but also their continuing rates of production, and so a
precise measure of their half-lives is not feasible from steady-state
data alone, it can be estimated that the CSF half-life of CCSctf is
less than 5 hours. Among the remaining markers, the half-life of
S100b was also relatively short, as has reported previously [29],
whereas 14-3-3 b and f forms, UCH-L1, NFHsmi-35, and CCSntf
had slower rates of decay after reaching peak levels.
Evidence that a set of 7 neurodegeneration biomarkers
predicts cerebral vasospasm, infarction, and functional
outcome
To begin evaluating the prognostic potential of this panel of
neurodegeneration biomarkers for aSAH, we compared the time
course and magnitude of marker elevations with the incidence and
severity of cerebral vasospasm, infarction, and brain dysfunction at
hospital discharge and long-term follow-up. Of the five confirmed
cases of moderate or severe cerebral vasospasm (cases 3, 9, 10, 21,
and 22), four showed large elevations in at least 6 neurodegen-
eration biomarkers within 7 days post-hemorrhage. Only case 22
experienced a moderate angiographic vasospasm that was not
accompanied by large elevations in the neurodegeneration
biomarker panel. Strikingly, case 22 also was the only example
of a moderate/severe vasospasm that was not accompanied by
brain infarction visible with diffusion-weighed imaging. In some
patients, biomarker changes were related temporally to the onset
of vasospasm. A clear example is provided by case 9, in which a
marked increase in blood flow velocities in the right middle and
anterior cerebral arteries started on day 6, the time when the
Lindegaard ratio first indicated vasospasm (confirmed by catheter
angiography). CSF levels of 7 of the 8 biomarkers were very low in
this case for up to 3 days post-hemorrhage, but thereafter showed
large spikes in 7 of the markers, starting at day 5. Thus,
neurodegeneration biomarker elevations occurred in this case
prior to the detection of cerebral vasospasm by ultrasonographic
and angiographic measures.
The temporal patterns of CSF changes in 6 neurodegeneration
biomarkers are shown in Figure 3 in relation to dichotomized
assessments of cerebral vasospasm and long-term brain functional
outcome. In the group of patients experiencing angiographic
vasospasm that was moderate or severe, levels of all 6
neurodegeneration biomarkers were elevated by from 3- to 10-
Figure 1. CSF changes in 3 neurodegeneration biomarkers after aneurysm rupture. (A) Western blot analyses of 14-3-3b, a calpain-cleaved
a-spectrin COOH-terminal fragment (CCSctf), and UCH-L1 in 3 aSAH cases at the indicated times post-rupture (in days). Case 25 is representative of
the subset of aSAH patients exhibiting large elevations in every neurodegeneration biomarker. Case 9, in contrast, shows a delayed increased in
neurodegeneration biomarkers starting on day 5 after aneurysm rupture. Case 19 is representative of the subset of aSAH cases exhibiting consistently
low or undetectable biomarker levels over the entire 10 day post-rupture period. (B) Western blot analysis of CCSctf levels 5 days post-rupture for 13
aSAH cases. Quantitative analysis (see Methods) showed that CSF levels of this biomarker vary by 100-fold across patients.
doi:10.1371/journal.pone.0028938.g001
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PLoS ONE | www.plosone.org 4 December 2011 | Volume 6 | Issue 12 | e28938Figure 2. Summary of neurodegeneration biomarker increases up to 10 days after severe aSAH. The figure depicts CSF levels for 8
neurodegeneration biomarkers measured serially in a cohort of 14 severe aSAH cases. The levels of each marker have been divided into 4 categories
as described in Methods , representing either low (blue), medium (yellow), high (orange), or very high (red).
doi:10.1371/journal.pone.0028938.g002
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significant at day 3, whereas the rise in CCSntf was significant at
days 3 and 5. These early biomarker increases are noteworthy in
that moderate to severe vasospasms typically became apparent
from 5–14 days post-rupture, as evidenced by vessel narrowing
visualized by angiography, and supported by increased anterior
blood flow velocities and worsening neurological signs. Neurode-
generation biomarker peak elevations also were related to long-
term outcome, as aSAH patients with poor long-term outcomes
(GOS-E 1-4/mRS4-6) had consistently and markedly higher CSF
levels of all 6 neurodegeneration biomarkers (up to 20-fold
increases) over the entire 10 day post-hemorrhage period.
Statistically significant increases were observed at 7–10 days for
the two calpain-derived a-spectrin derivatives CCSctf and
CCSntf, 14-3-3f, and NSE, while CSF levels of UCH-L1 and
NSE were significantly related to long-term outcome at earlier
post-hemorrhage times.
The data comparing peak levels of the 8 biomarkers to poor
functional outcome and pathophysiological processes contributing
to it are summarized in Tables 2, 3, 4, 5, 6. The peak
neurodegeneration biomarker levels from 5–10 days after
aneurysm rupture were related to the initial severity of the SAH
as determined by the Hunt-Hess grade. Peak marker increases
were up to 6-fold higher in patients presenting with Hunt-Hess
grades of 4 or 5 compared with grades of 2 or 3 (Table 2). In
addition, the peak CSF concentrations of all 8 markers were from
4 to 20 fold higher in cases with focal infarcts detected by
diffusion-weighed MRI, and moderate-to-severe vasospasms
detected by angiography and supported by ultrasonography.
The peak CSF level of CCSctf from 3–10 days post-hemorrhage
correlated significantly with the incidence of infarction (Table 3).
CSF 14-3-3b, CCSntf, and NSE also were early predictors of the
subsequent development of vasospasm, with their peak levels
within the first 3 days correlating significantly with angiographic
vasospasm that was moderate or severe (Table 4).
In addition to relating to the radiologic, angiographic, and
ultrasonographic evidence of cerebral infarction and vasospasm,
peak levels of all 8 of the markers were related strongly to the
severity of brain dysfunction assessed at the time of hospital
discharge. Case 12 did not show evidence of vasospasm or brain
infarction, but had a second aneurysm rupture on day 10 that
proved fatal. This case was excluded from comparative analyses of
neurodegeneration biomarker elevations in relation to outcomes.
For the remaining cases, those that either expired or were
discharged to a nursing facility had higher CSF levels of all 8
biomarkers ranging from 3 to 10-fold when compared with cases
discharged either to home or an in-patient rehabilitation facility.
The peak elevations in CCSctf, 14-3-3f, UCH-L1, CCSntf, and
NSE were correlated significantly with poor discharge outcome
(Table 5).
Figure 3. Time courses for 6 CSF neurodegeneration biomark-
ers in relation to functional outcome and the severity of
cerebral vasospasm. Long-term outcome was dichotomized to either
poor (closed circles: GOS-E =1–4; mRS =4–6) or good (open boxes:
GOS-E =5–8; mRS =1–3), while angiographic vasospasm was
categorized as either moderate/severe (closed circles) or absent/mild
(open boxes) as described in Methods. Mean CSF levels of each
neurodegeneration biomarker at the indicated times post-aneurysm
rupture (in days) are shown with the standard error of the mean.
Statistically significant between-group differences (p,0.05) are identi-
fied by asterisk. In cases for which CSF samples were available at both 7
and 10 days post-rupture, the higher marker level was considered.
doi:10.1371/journal.pone.0028938.g003
Table 2. Relationship between peak CSF neurodegeneration biomarker levels and hemorrhage severity.
Grade CCSctf NFHsmi35 14-3-3b 14-3-3f UCH-L1 CCSntf NSE S100b
2–3 0.5 +/- 0.2 12.9 +/- 11.4 7.7 +/- 4.5 5.3 +/- 1.2 2.8 +/- 1.9 8.6 +/- 2.0 2.3 +/- 1.2 21 +/- 11
4–5 1.7 +/- 0.4 17.1 +/- 12.8 13.8 +/- 5.3 16.5 +/- 6.0 7.0 +/- 2.4 33.1 +/- 16.7 13.1 +/- 4.4 39 +/- 14
P value 0.03 0.81 0.39 0.09 0.21 0.17 0.04 0.35
The mean (+/- S.E.M.) peak level of each biomarker from 3–10 days post-rupture is depicted in relation to the initial severity of the aneurysm dichotomized according to
the Hunt-Hess grade.
doi:10.1371/journal.pone.0028938.t002
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with poor functional outcome at 6-9 months as assessed by the
GOSE and mRS. For 6 of the 7 neurodegeneration markers, peak
marker levels measured within 10 days of aneurysm rupture were
from 2 to 6-fold higher in patients with poor long-term functional
outcomes. Peak CSF levels of both CCSctf and NSE measured
from 3-10 days post-rupture differed significantly between GOSE
and mRS dichotomized to good (GOSE 5-8/mRS 1-3) or poor
(GOSE 1-4/mRS 4-6) brain functional outcome (Table 6).
Discussion
In this report we describe a panel of neurodegeneration
biomarkers that rise up to 100-fold in CSF following severe aSAH
and collectively may be early predictors of pathophysiological
complications and poor functional outcome. In addition to the
widely studied NSE and S100b, 6 additional neuron-enriched
proteins that are released from degenerating neurons increase
within a week of aneurysm rupture. Peak levels of a group of 6
markers (CCSctf, CCSntf, 14-3-3b, 14-3-3f, UCH-L1, and NSE)
correlate significantly with moderate-to-severe cerebral vasospasm,
focal infarction, and lasting brain dysfunction, whereas no single
marker correlates with every measure. These findings identify a
biomarker panel meriting consideration as clinically useful
prognostic measures of ischemic brain damage.
A major challenge in aSAH research has been to establish
biochemical markers capable of predicting the development of
DCI and lasting brain dysfunction. Such markers could serve as
surrogate endpoints for controlled clinical research studies of the
comparative efficacy of treatment interventions designed to
normalize physiology, reduce DCI, and improve outcome. A
handful of proteins have been studied in this regard, including the
neuron-enriched NSE and neurofilament L, along with the glial-
enriched S100b, glial fibrillary acidic protein, and myelin basic
protein [7-13], but unfortunately none has proven a reliable
surrogate measure for the vasospasm, DCI, or poor functional
outcome of aSAH. Recently, we and others identified additional
proteins released from degenerating neurons whose efflux from the
injured brain could be potential surrogate measures for ischemic
brain damage, including two calpain-derived proteolytic fragments
of the actin-binding cytoskeletal protein a-spectrin, the ubiquitin
ligase UCH-L1, three distinct phosphoforms of the high molecular
weight neurofilament subunit NFH, and the b and f isoforms of
14-3-3 protein [9–12,14–18]. We report that no single marker
correlates significantly with every measure of complications and
outcomes, consistent with prior studies in aSAH. Instead, we
present evidence from collective analyses of a new panel of 7
neurodegeneration biomarkers along with the astroglial-derived
S100b that combinations of 6 of the markers predict moderate to
severe cerebral vasospasm (14-3-3b, CCSntf, NSE; Table 4), focal
ischemic brain damage (CCSctf; Table 3), and brain dysfunction
at hospital discharge (CCSctf, 14-3-3f, UCH-L1, CCSntf, NSE;
Table 5) and long-term follow-up (CCSctf, NSE; Table 6). These
data support the hypothesis that a panel of neurodegeneration
biomarkers has far more discriminative power than any single
marker alone to distinguish pathophysiological complications and
brain damage following aSAH, and potentially other acute
neurodegenerative disorders as well. The significant correlations
between neurodegeneration biomarker increases, long-term brain
dysfunction, and the cerebral vasospasm and infarction that
contribute to the lasting dysfunction, coupled with prior reports
linking these markers to multiple forms of ischemia- and trauma-
induced acute brain damage [11,12,14–19], suggest that the
marker panel could serve as a surrogate endpoint for therapeutic
response in controlled clinical trials. The responsiveness of the
neurodegeneration biomarkers to interventions that reduce
pathophysiological complications and improve functional out-
comes will require further study.
Not only are delayed elevations in the panel of neurodegener-
ation biomarkers related to complications and outcomes after
severe aSAH, but their early peak levels measured within 3 days of
aneurysm rupture may predict the subsequent development of
moderate to severe cerebral vasospasm. Although the initial
assessment of aneurysm severity by the Fisher, Hunt-Hess, or
WFNS grade has been associated with the subsequent risk for
cerebral vasospasm and DCI [30,31], some studies report the
Table 3. Relationship between peak CSF neurodegeneration biomarker levels and neuroradiologically confirmed cerebral
infarction.
Infarction CCSctf NFHsmi35 14-3-3b 14-3-3f UCH-L1 CCSntf NSE S100b
Yes 1.8 +/- 0.4 17.3 +/- 12.7 18.9 +/- 6.9 13.7 +/- 6.8 6.3 +/- 2.8 14.5 +/- 5.0 10.0 +/- 4.5 40.1 +/- 12.5
No 0.3 +/- 0.1 1.2 +/- 0.8 3.3 +/- 0.5 3.6 +/- 0.8 0.6 +/- 0.1 4.8 +/- 1.1 0.5 +/- 0.2 8.4 +/- 2.1
P value 0.03 0.34 0.11 0.27 0.14 0.16 0.13 0.08
The mean (+/- S.E.M.) peak level of each biomarker from 3–10 days post-rupture is depicted in relation to infarction detectable by diffusion weighted MRI.
doi:10.1371/journal.pone.0028938.t003
Table 4. Relationship between early CSF neurodegeneration biomarker increases and the severity of cerebral vasospasm.
Vasospasm CCSctf NFHsmi35 14-3-3b 14-3-3f UCH-L1 CCSntf NSE S100b
No/Mild 1.6 +/- 0.5 4.7 +/- 2.5 1.3 +/- 0.4 2.6 +/- 0.6 2.0 +/- 0.6 3.2 +/- 0.9 1.1 +/- 0.3 50 +/- 22
Mod/Severe 10.7 +/- 8.4 3.7 +/- 0.8 20.6 +/- 9.7 17.3 +/- 12.7 12.9 +/- 8.9 17.9 +/- 6.9 14.7 +/- 6.8 350 +/- 285
P value 0.22 0.77 0.04 0.19 0.17 0.03 0.04 0.24
The mean (+/- S.E.M.) peak level of each biomarker within 3 days of aneurysm rupture is depicted in relation to dichotomized severity of angiographic vasospasm.
doi:10.1371/journal.pone.0028938.t004
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at a preclinical stage of aSAH-induced cerebral vasospasm might
have implications for preventive treatments of vasospasm by
improving its early detection and widening the therapeutic
window beyond that achievable from clinical, ultrasonographic,
and angiographic information. A driving force for the rapid rise in
CSF neurodegeneration biomarkers could be early brain injury
that shortly follows aneurysm rupture, and is thought to be a
strong determinant of subsequent mortality and morbidity [33].
Consistent with the importance of primary injury mechanisms, the
stratification of hemorrhage severity by the Hunt-Hess grade was
significantly related to the delayed CSF elevations in the
neurodegeneration biomarkers CCSctf and NSE occurring 7–10
days later (Table 2).
The present single-site clinical study is limited by the small
sample size, but provides preliminary evidence with internal,
external, and mechanistic support that a panel of neurodegener-
ation biomarkers might be prognostic measures for severe aSAH.
Rather than simply relying on only one or two markers, we
describe that 6 proteins released by degenerating neurons rise
markedly in association with lasting brain dysfunction. This
association is strengthened further by the relationships between the
neurodegeneration biomarker elevations and pathophysiological
processes (cerebral vasospasm and infarction) contributing to long-
term dysfunction. The link between these neurodegeneration
biomarker increases and acute brain damage is not limited to
SAH, since several members of the marker panel are also
associated with other forms of ischemia- and trauma-induced
brain injury [14–21]. Two members of the marker panel, the N-
and C-terminal derivatives of a-spectrin, are mechanism-based
markers, in that they are derived from proteolytic processing by
the calpain family of cysteine proteases that play an important role
in neuronal necrosis [20,34]. Using a single antibody reactive not
only with a calpain- but also a caspase-derived a-spectrin
fragment, we provide CSF biomarker evidence that calpain-driven
necrosis predominates over caspase-mediated apoptosis as a
neurodegenerative mechanism in the human brain following
severe aSAH (Figure 1). These data are consistent with
histopathological and biomarker reports of the prevalence of
calpain-driven necrosis in experimental models of ischemic and
traumatic brain injury, as well as prior studies of these mechanism-
based neurodegeneration biomarkers in humans following surgi-
cally-induced circulation arrest or severe TBI [15-18,23,25].
In light of the small sample size evaluated thus far, the
application of neurodegeneration biomarker elevations as early
predictors of the subsequent development of cerebral vasospasm,
infarction, and long-term brain dysfunction in SAH will require
further study in larger patient cohorts. In addition to early
prognosis, there are several additional features of aSAH that may
be addressed by a panel of neurodegeneration biomarkers in larger
multi-center clinical studies. Among the panel members are
protein components of both neurons and astroglia, and the
neuron-enriched proteins differ in both their brain regional and
subcellular localizations. For example, various phosphoforms of
NFH have been proposed as selective markers for axonal
vulnerability following brain injury [35]. Furthermore, although
all members of the neurodegeneration biomarker panel are widely
expressed across the neuraxis, their expression levels are not
uniform across all brain regions and neuronal types. Consequent-
ly, it may be possible to use the current or a more extensive next-
generation panel of biomarkers that include proteins with
restricted expression across brain regions, cell populations, and
subcellular compartments to inform on a per-patient basis the
anatomical localization of acute brain damage, the susceptibility of
distinct cell types, and the contribution of axonal injury.
In conclusion, this study provides evidence that a panel of 6
neurodegeneration biomarkers might predict cerebral vasospasm,
infarction, and lasting brain dysfunction following severe aSAH.
The findings suggest that a panel of neurodegeneration biomarkers
could have enhanced discriminative power over any single marker
for predicting pathophysiological complications and the ensuing
acute brain damage and lasting brain dysfunction. Such a
neurodegeneration biomarker panel could be valuable as surrogate
endpoints for controlled clinical evaluation of treatment interven-
tions designed to mitigate ischemic brain damage and improve
functional outcome. More extensive clinical study of the
neurodegeneration biomarkers described here in well-monitored
patients will be required to define their diagnostic, prognostic,
mechanistic, and experimental therapeutic applications in aSAH
and other forms of acute brain damage.
Table 5. Relationship between peak CSF neurodegeneration biomarker levels and outcome at hospital discharge.
Outcome CCSctf NFHsmi35 14-3-3b 14-3-3f UCH-L1 CCSntf NSE S100b
Dead, Nursing 2.3 +/- 0.6 27.1 +/- 22.1 20.9 +/- 7.7 24.7 +/- 8.4 9.8 +/- 3.5 53.8 +/- 25.5 21.3 +/- 4.0 54 +/- 22
Rehab/Home 0.7 +/- 0.2 10.9 +/- 8.8 6.9 +/- 3.5 4.8 +/- 1.0 2.4 +/- 1.5 7.9 +/- 1.6 2.1 +/- 0.9 22 +/- 9
P value 0.005 0.42 0.08 0.004 0.04 0.02 0.0001 0.13
The mean (+/- S.E.M.) peak level of each biomarker from 3–10 days post-rupture is depicted in relation to dichotomized discharge outcome.
doi:10.1371/journal.pone.0028938.t005
Table 6. Relationship between peak CSF neurodegeneration biomarker levels and long-term outcome.
Outcome CCSctf NFHsmi35 14-3-3b 14-3-3f UCH-L1 CCSntf NSE S100b
GOSE 5-8 0.6 +/- 0.2 17.8 +/- 15.8 9.4 +/- 6.3 4.6 +/- 2.1 3.6 +/- 2.7 9.0 +/- 2.5 2.9 +/- 1.6 27 +/- 15
GOSE 1-4 2.0 +/- 0.5 22.3 +/- 17.8 17.5 +/- 6.8 20.5 +/- 7.7 8.2 +/- 3.2 44.3 +/- 21.9 17.3 +/- 5.0 127 +/- 59
P value 0.04 0.86 0.41 0.08 0.29 0.15 0.03 0.14
The mean (+/- S.E.M.) peak level of each biomarker from 3–10 days post-rupture is depicted in relation to long-term outcome dichotomized according to the Glasgow
Outcome Scale - Extended.
doi:10.1371/journal.pone.0028938.t006
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